Article R5212-24 of the French Public Health Code
The Agence nationale de sécurité du médicament et des produits de santé submits to its control a sample of each batch of the substance which, if used separately from the medical device in which it is incorporated as an integral part, is likely to be considered as a blood-derived medicinal product, except in the case of a batch originating from another Member State of the European Union or party to…